Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3199 Turbuhaler · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dry powder for oral inhalation |
| 2 | PLACEBO_COMPARATOR | Dry powder for oral inhalation |
| Name | Type | Description |
|---|---|---|
| AZD3199 Turbuhaler® | DRUG | 240, 720 and 2160 μ g, single and multiple (o.d. for 12 days) |
| Placebo Turbuhaler® | DRUG | single and multiple (o.d. for 12 days) |
Inclusion Criteria: * Be healthy Japanese volunteers, both of the volunteer's parents, and all grandparents must be Japanese. The volunteer must have been born in Japan, have a valid Japanese passport and must not have lived outside Japan for for more than 5 years. * BMI 18 - 27, Weight 50 - 85 kg ...
AZD3199 Turbuhaler is an investigational small molecule being developed by AstraZeneca PLC (AZN). It is currently in Phase 1 clinical development. The drug is administered via a Turbuhaler device and has been studied in healthy volunteers.
AZD3199 Turbuhaler is being studied in healthy volunteers. The completed Phase 1 trial assessed its safety, tolerability, and pharmacokinetics in healthy Japanese male participants. It is not approved for any disease indication and remains in early clinical development.
AZD3199 Turbuhaler is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate the drug's safety and pharmacokinetic profile in healthy subjects.
AZD3199 Turbuhaler is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received regulatory approval and is not yet available for clinical use.
AZD3199 Turbuhaler has one completed clinical trial, NCT00772759, titled 'Assess Safety, Tolerability and PK of AZD3199 in Japanese.' This Phase 1 study enrolled 27 healthy male participants in the United Kingdom and was a randomized, double-blind, placebo-controlled trial.
AZD3199 Turbuhaler refers to the specific formulation of the drug AZD3199 delivered via a Turbuhaler inhalation device. The clinical trial NCT00772759 evaluated this formulation in healthy volunteers to assess its safety, tolerability, and pharmacokinetics.